Arkolith/Stocks/KYNTRA BIO, INC.

KYNTRA BIO, INC.

Cross-source read

No active 13F manager changed its position in KYNTRA BIO, INC. last quarter. Over the last 180 days, 1 insider bought and none sold, a net +$20K in open-market trades.

Tracked 13F holders
0
13F value (tracked)
$0
Smart-money readMixed
Net sellingNet buying
Funds · active managers, latest 13F
0 adding · 0 trimming
Insiders · Form 4 open-market, 180d
1 buying · 0 selling · +$20K
US House · STOCK Act, 180d
0 buying · 0 selling

The legs disagree, or only one of them leans.

Who owns KYNTRA BIO, INC.?

0 tracked 13F filers · ranked by shares held

Not held in any tracked 13F filing yet.

Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.

Insider activity (Form 4)

Full insider page →
Buys · 180d
$20K
1 insider
Net · 180d
$20K
1 open-market transaction
DateInsiderRoleActionSharesValue
May 14, 2026Wettig ThaneCEO, DirectorBuy (P)3K$20K
Nov 17, 2025Wettig ThaneCEO, DirectorBuy (P)3K$25K
Nov 13, 2025Wettig ThaneCEO, DirectorBuy (P)1K$9K
Jun 30, 2025Schoeneck James ADirectorBuy (P)24K$119K
Mar 24, 2025Wettig ThaneCEO, DirectorBuy (P)145K$51K
Mar 21, 2025Schoeneck James ADirectorBuy (P)50K$17K
Mar 20, 2025Schoeneck James ADirectorBuy (P)250K$88K
Jun 12, 2024Adib DeyaaChief Medical OfficerBuy (P)22K$26K
Mar 7, 2024Wettig ThaneCEOBuy (P)50K$96K
Sep 1, 2023Henderson Jeffrey WilliamDirectorSell (S)2K$2K
Aug 4, 2023Henderson Jeffrey WilliamDirectorSell (S)2K$4K
Jul 11, 2023Henderson Jeffrey WilliamDirectorSell (S)2K$5K

Do institutions, insiders and Congress agree?

Mixed signals

Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.

SEC EDGAR 13F + Form 4 + US House STOCK Act{ }get_ticker_confluence · API & MCP

Signals by source

Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive

SourceBuyingSellingNet
13F funds
Top 100 holders by value, passive included; the hero counts active managers only
00–
Insiders
Form 4 open-market
10+$20K
US House
STOCK Act trades
00$0

Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.

Recent filings

15 most recent

Keep exploring

Connected entities for KYNTRA BIO, INC.

More on KYNTRA BIO, INC.

Browse more

All tracked stocks A–ZKYNTRA BIO, INC. insider filings13F funds A–Z
Build

Ask your agent what changed in KYNTRA BIO, INC.

This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.

Get a key Compare plansWorkflow docs
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/stocks/FGEN/capital-change-brief"
Ask your agent
Use Arkolith's capital_change_brief for KYNTRA BIO, INC..
Tell me what changed, whether insider activity
corroborates it, and cite the SEC evidence.

13F holdings + Form 4 insider transactions + the live filing stream, joined for FGEN. Filings are public domain, sourced to SEC EDGAR.